The long term goal of this work was to develop an in vivo model of metastasis in which it would be possible to a) quantitatively analyze the individual steps of this process, b) to identify tumor cell properties which are crucial for their spread, and c) to determine in what way the alteration of these properties affects metastasis. the latter would provide an insight to the mechanism of tumor cell spread and, possibly, a target for therapy. the work is centered on proteolytic enzymes, such as urokinase type plasminogen activator (uPA), plasmin and collagenases, which are able to degrade biological barriers and thus may facilitate the escape of cells from a primary tumor and their dissemination to distant sites. Using chick embryos and human tumor cells we developed an assay in which """"""""spontaneous"""""""" metastasis, local invasion and extravasation (exit from the blood vessels) could be quantitated. We established that uPA had a crucial role in metastasis and that at least one step, the local invasion, was dependent on active uPA. Moreover, we showed that only cells which, in addition to uPA, also expressed surface receptor for uPA (uPAR) were locally invasive. By indirect means we also showed that interstitial collagenase (IC) may be involved in invasion. In the current proposal we will adapt the model to the quantitative study of invasion of blood vessels walls, which, to the best of our knowledge, will be the first such in vivo assay. Once developed, we will explore the possibility of adapting it in the future for testing the blood vessel invading capacity of fresh human tumors. The main emphasis of the current proposal is on direct examination of the uPAR and IC roles in the processes leading to metastasis; uPAR will be studied both for its capacity to concentrate proteolytic activity on the surface of tumor cells, and also as a possible mediator of enhanced tumor cell motility. These studies will be conducted in two hosts, chick embryos and nude mice. uPAR and IC will be inhibited in two malignant human carcinoma cells (HEp3 and Colo 16) by antisense RNA. These cells will be stably transfected by constructs containing fragments of uPAR and IC cDNAs in antisense orientation; appropriate controls will be included. Cells inhibited in a single, defined property, will be tested for their ability to complete individual steps of metastasis. This approach should enable the identification of tumor cells properties which cannot be compensated by alternative pathways and thus are rate limiting for the entire process. The mechanism(s) by which the metastatic process is interrupted will also be explored.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
2R01CA040758-07A1
Application #
3181066
Study Section
Pathology B Study Section (PTHB)
Project Start
1985-08-01
Project End
1997-07-31
Budget Start
1993-08-01
Budget End
1994-07-31
Support Year
7
Fiscal Year
1993
Total Cost
Indirect Cost
Name
Mount Sinai School of Medicine
Department
Type
Schools of Medicine
DUNS #
City
New York
State
NY
Country
United States
Zip Code
10029
Franco, Paola; Vocca, Immacolata; Carriero, Maria V et al. (2006) Activation of urokinase receptor by a novel interaction between the connecting peptide region of urokinase and alpha v beta 5 integrin. J Cell Sci 119:3424-34
Wang, Long G; Ossowski, Liliana; Ferrari, Anna C (2004) Androgen receptor level controlled by a suppressor complex lost in an androgen-independent prostate cancer cell line. Oncogene 23:5175-84
Aguirre-Ghiso, Julio A; Ossowski, Liliana; Rosenbaum, Sarah K (2004) Green fluorescent protein tagging of extracellular signal-regulated kinase and p38 pathways reveals novel dynamics of pathway activation during primary and metastatic growth. Cancer Res 64:7336-45
Aguirre Ghiso, Julio A (2002) Inhibition of FAK signaling activated by urokinase receptor induces dormancy in human carcinoma cells in vivo. Oncogene 21:2513-24
Liu, David; Aguirre Ghiso, Julio; Estrada, Yeriel et al. (2002) EGFR is a transducer of the urokinase receptor initiated signal that is required for in vivo growth of a human carcinoma. Cancer Cell 1:445-57
Aguirre-Ghiso, J A; Liu, D; Mignatti, A et al. (2001) Urokinase receptor and fibronectin regulate the ERK(MAPK) to p38(MAPK) activity ratios that determine carcinoma cell proliferation or dormancy in vivo. Mol Biol Cell 12:863-79
Wang, L G; Ossowski, L; Ferrari, A C (2001) Overexpressed androgen receptor linked to p21WAF1 silencing may be responsible for androgen independence and resistance to apoptosis of a prostate cancer cell line. Cancer Res 61:7544-51
Ossowski, L; Aguirre-Ghiso, J A (2000) Urokinase receptor and integrin partnership: coordination of signaling for cell adhesion, migration and growth. Curr Opin Cell Biol 12:613-20
Gao, M; Ossowski, L; Ferrari, A C (1999) Activation of Rb and decline in androgen receptor protein precede retinoic acid-induced apoptosis in androgen-dependent LNCaP cells and their androgen-independent derivative. J Cell Physiol 179:336-46
Aguirre Ghiso, J A; Kovalski, K; Ossowski, L (1999) Tumor dormancy induced by downregulation of urokinase receptor in human carcinoma involves integrin and MAPK signaling. J Cell Biol 147:89-104

Showing the most recent 10 out of 25 publications